Spelt Lidewij, Sasor Agata, Ansari Daniel, Hilmersson Katarzyna Said, Andersson Roland
Department of Surgery, Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden
Department of Pathology, Skåne University Hospital, Lund, Sweden.
Anticancer Res. 2018 Jan;38(1):313-320. doi: 10.21873/anticanres.12224.
BACKGROUND/AIM: To assess the expression of cancer stem cell (CSC) markers CD44, CD133 and CD24 in colon cancer liver metastases and analyse their predictive value for overall survival (OS) and disease-free survival (DFS) after liver resection.
Patients operated on for colon cancer liver metastases were included. CSC marker expression was determined through immunohistochemistry analysis. OS and DFS were compared between marker-positive and marker-negative patients. Multivariate analysis was performed to select predictive variables for OS and DFS.
CD133-positive patients had a worse DFS than CD133-negative patients, with a median DFS of 12 and 25 months (p=0.051). Multivariate analysis selected CD133 expression as a significant predictor for DFS. CD44 and CD24 were not found to predict OS or DFS.
CD133 expression in colonic liver metastases is a negative prognostic factor for DFS after liver resection. In the future, CD133 could be used as a biomarker for risk stratification, and possibly for developing novel targeted therapy.
背景/目的：评估癌症干细胞（CSC）标志物CD44、CD133和CD24在结肠癌肝转移灶中的表达，并分析其对肝切除术后总生存期（OS）和无病生存期（DFS）的预测价值。
纳入接受结肠癌肝转移手术的患者。通过免疫组织化学分析确定CSC标志物的表达。比较标志物阳性和阴性患者的OS和DFS。进行多变量分析以选择OS和DFS的预测变量。
CD133阳性患者的DFS比CD133阴性患者差，中位DFS分别为12个月和25个月（p=0.051）。多变量分析选择CD133表达作为DFS的显著预测因子。未发现CD44和CD24可预测OS或DFS。
结肠肝转移灶中CD133的表达是肝切除术后DFS的负性预后因素。未来，CD133可作为风险分层的生物标志物，并可能用于开发新型靶向治疗。
